White tailed deer

White tailed deer Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 11 adverse event reports for White tailed deer, distributed across 0 distinct breeds currently tracked in the system. Of those reports, 4 involved a death outcome — producing a 3640.0% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for White tailed deer are Lack of efficacy - NOS (4 reports), Death (3 reports), No sign (2 reports), INEFFECTIVE, ANESTHESIA (2 reports), with Lack of efficacy - NOS leading the reaction traffic at 4 submissions. On the product side, Tiletamine Hcl; Zolazapam Hcl is the single most-referenced drug with 2 reports, followed by Tiletamine + Zolazepam (2), Progesterone (2), Tulathromycin (2). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species — a useful starting point when comparing White tailed deer reporting patterns against other companion animals in the dataset.

Of the 11 White tailed deer reports with a coded outcome, Outcome Unknown accounts for the largest share at 45.5%. Annual submission volume spans 2,012 to 2,017 reports across the 6 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 0 tracked white tailed deer breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling — causation requires clinical investigation beyond what these aggregates can provide.